Bellerophon to Present at the JMP Securities Life Sciences Conference

By GlobeNewswire,  June 13, 2019, 08:00:00 AM EDT

WARREN, N.J., June 13, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, announced today that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the JMP Securities Life Sciences Conference, being held June 19-20, 2019, at the St. Regis New York Hotel in New York City.

Bellerophon Presentation Details

Date:       Thursday, June 20
Time:       11:00 AM Eastern Time
Location:       St. Regis New York Hotel, New York, NY
Webcast:       http://wsw.com/webcast/jmp39/blph/

About Bellerophon

Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing multiple product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery system.  For more information, please visit www.bellerophon.com.

At Bellerophon:       At LifeSci Advisors:
Fabian Tenenbaum, Chief Executive Officer        Brian Ritchie
(908) 574-4767       (212) 915-2578

Source: Bellerophon Therapeutics, Inc.

This article appears in: News Headlines

Referenced Stocks: BLPH

Today's Market Activity

NASDAQ 7796.66
-40.47  ▼  0.52%
DJIA 26089.61
-17.16  ▼  0.07%
S&P 500 2886.98
-4.66  ▼  0.16%
Data as of Jun 14, 2019